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INTRODUCTION: 
Malaria is a mosquito-borne infectious disease caused by 
eukaryotic protist of the genus Plasmodium. It is 
widespread in tropical and subtropical regions, including 
parts of the Asia, Americas and Africa. Each year, there 
are approximately 350–500 million cases of malaria, 
killing between one and three million people, the majority 
of whom are young children. Several drugs are used for the 
treatment of malaria. Use of prophylactic drugs is seldom 
practical for full-time residents of malaria-endemic areas, 
and their use is usually restricted to short-term visitors and 
travelers to malarial regions. This is due to the cost of 
purchasing the drugs, negative side effects from long-term 
use, and because some effective anti-malarial drugs are 
difficult to obtain outside of wealthy nations. Quinine was 
used starting in the 17th century as a prophylactic against 
malaria. The development of more effective alternatives 
such as chloroquine, primaquine and quinacrine in the 20th 
century reduced the reliance on quinine. Today, quinine is 
still used to treat chloroquine resistant Plasmodium 
falciparum, as well as severe and cerebral stages of 
malaria, but is not generally used for prophylaxis. 
Chemically the antimalarial drugs are classified as Aryl 
amino alcohols (Quinine, quinidine, mefloquine, 
halofantrine), 4-aminoquinolines (Chloroquine, 
amodiaquine), Folate synthesis inhibitors (sulphones, 
sulphonamides, proguanil, chloroproguanil, 
diaminopyrimidine like pyrimethamine) and 8-
aminoquinolines (Primaquine, WR238, 605) etc. The 
mechanism of action of CHQ is unclear. Being alkaline, 
the drug reaches high concentration within the food 
vacuoles of the parasite and raises its pH11. CHQ inhibits 
the parasitic enzyme heme polymerase that converts the 
toxic heme into non-toxic hemazoin, thereby resulting in 
the accumulation of toxic heme within the parasite. Other 
mechanisms suggested include formation of drug-heme 
complex and intercalation of the drug with the parasitic 
DNA12,13 .Almost 90% of the administered CHQ is 
absorbed from gut and rapidly absorbed from intra 
muscular and subcutaneous sites. It has a large distribution 
volume due to extensive sequestration in tissues of liver, 
spleen, kidney, lung etc. Hence a larger loading dose is 
generally required. Therapeutic blood levels persist for 6-
10 days and elimination half-life is 1-2 months. Half of the 
drug is excreted unchanged by the kidneys, remaining is 
converted to active metabolites in the liver. Dose - Oral- 
10mg/kg stat., then three doses of 5 mg/kg, over 36-48 
hours.It has been found that CHQ have some adverse 
effects upon administration. It can cause dizziness, 
headache, diplopia, disturbed visual accommodation, 
nausea, malaise, and pruritus of palms, soles and scalp. 
CHQ can also cause visual hallucinations, confusion, and 
occasionally frank psychosis. When used as prophylactic 
at 300 mg of the base/ week, it can cause retinal toxicity 
after 3-6 years (i.e. after 50-100 g of CHQ). Intra muscular 
injections of CHQ can cause hypotension and cardiac 
arrest, particularly in children. CHQ forms intercalated 
complexes with DNA and acts as an inhibitor of DNA 
synthesis and repai It is deposited in tissues and can cross 
the placenta . CHQ is also reported to induce teratogenic 
effects in rats  .Mutations are changes in the DNA 
sequence of a cell's genome and are caused by radiation, 
viruses, transposons, errors that occur during meiosis or 
DNA replication and various chemicals. They can also be 
induced by the organism itself, by cellular processes such 
as hypermutation. Mutation can result in several different 
types of change in DNA sequences; these can either have 
no effect or alter the product of a gene that prevents the 
gene from functioning properly or completely. If a 
mutation changes a protein produced by a gene, this will 
probably be harmful, with about 70 percent of these 
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mutations having damaging effects, and the remainder 
being either neutral or weakly beneficial. Due to the 
damaging effects that mutations can have on cells, 
organisms have evolved mechanisms such as DNA repair 
to remove mutations.A laboratory test developed by 
biochemist Bruce N. Ames to determine the possible 
carcinogenic nature of a substance. The Ames test involves 
using a particular strain of the bacteria Salmonella 
typhimurium that lacks the ability to synthesize histidine 
and is therefore very sensitive to mutation. The bacteria 
are inoculated into a medium deficient in histidine but 
containing the test compound. If the compound results in 
DNA damage with subsequent mutations, some of the 
bacteria will regain the ability to synthesize histidine and 
will proliferate to form colonies. The culture is evaluated 
on the basis of the number of mutated bacterial colonies it 
produced. The ability to replicate mutated colonies leads to 
the classification of a substance as probably carcinogenic. 
Since the standard tests for carcinogenicity done on 
rodents take years to complete and are expensive to do. 
The procedure is described in a series of papers from the 
early 1970s by Bruce Ames and his group at the University 
of California, Berkeley. 
The test uses several strains of the bacterium Salmonella 
typhimurium that carry mutations in genes involved in 
histidine synthesis, so that they require histidine for 
growth. For mutagenicity assays, Salmonella strains 
TA97a, TA98, TA100 and TA102 are usually used. Each 
tester strain contains a different type of mutation in 
histidine operon. In addition to the histidine mutation the 
standard tester strains contain other mutations that greatly 
enhance their ability to detect mutagens. One mutation 
(rfa) causes partial loss of the lipopolysaccharide barrier 
coating the surface of the bacteria and increases 
permeability to large molecules such as benzo [a] pyrene 
that do not penetrate the normal cell wall . The other 
mutation uvrB is a deletion of a gene coding for the DNA 
excision repair system, resulting in greatly increased 
sensitivity in detecting many mutagens1. The standard 
tester strains TA97a, TA98, TA100, TA102 contain R-
factor plasmid, pKM101. These four strains were used 
since they were recommended for the routine mutagenicity 
and antimutagenicity assay of different drugs and 
chemicals7 TA97a and TA98 detect frame shift mutagens 
TA100 detects base pair mutagens. Maron and Ames 
(1983) primarily recommended both TA98 and TA100 for 
routine mutagenicity assay. TA102 contains A-T base 
pairs at site of the mutation (determined by DNA sequence 
analysis) in contrast to the other Salmonella tester strains 
that detect mutagens damaging the G-C base pair. In this 
tester strain the mutation has been introduced into a 
multicopy plasmid as a result around 30 copies of the 
mutant gene exist for back mutation7 . 
Some chemicals (called pro-mutagens) are not mutagenic 
unless metabolized to more active derivatives. Liver 
enzymes that normally detoxify harmful metabolic 
intermediates are often responsible for the activation of 
pro-mutagens into mutagens. For example, benzo (a) 
pyrene is not mutgenic but it is converted by liver enzymes 
to diolepoxides which are potent mutagens and 
carcinogens. Therefore, to test for such pro-mutagens, an 
extract of rat liver enzymes is included in the reversion 
assay. 
In both toxicity and mutation tests, tester strains are 
combined with S9 mix or buffer, test or control article, a 
trace of histidine or tryptophan and molten agar. The 
bacteria use the trace histidine or tryptophan to undergo 
several cell divisions, but will stop growing once they have 
run out, leaving a characteristic “background lawn” that 
decreases in density with increasing toxicity. After 48 
hours, only those cells that have undergone a reverse 
mutation turning the essential gene back on have survived, 
producing mutant colonies. The background lawn density 
is scored followed by counting the number of revertant 
colonies. Mutation results are reported as revertants per 
plate.  
METHOD: 
Animals 
Charles River male rats of 150-175 g. were used for the 
preparation of liver homogenate (S9) for bacterial 
antimutagenicity assays. They were kept four per cage 
with husk bedding.  Animals were received from the 
animal house of our institute and were fed balanced rodent 
pellet diet (Gold Mohar, Lipton Ltd., Chandigarh, India) 
and water ad libitum. The environment had a controlled 
12h light and 12h dark cycle. Ambient temperature and 
relative humidity were 22º ± 2ºC and 55% ± 5% 
respectively.  
Chemicals 
Chloroquine phosphate was purchased from the local 
market. Biotin, histidine, ampicillin trihydrate, sodium 
azide (SA), 4-nitro-o-phenylenediamine (NPD),were 
supplied from Sigma Chemical Company (St. Louis, MO); 
agar and nutrient broth were supplied from HiMedia 
laboratories Ltd (India). Magnesium sulfate, magnesium 
chloride, potassium chloride, citric acid monohydrate, 
dibasic potassium phosphate, sodium ammonium 
phosphate, sodium hydroxide, glucose were purchased 
from E. Merck Limited (Mumbai, India).  
Bacterial Strains  
For mutagenicity assays, Salmonella strains TA98 and 
TA100 were used. Each tester strain contains a different 
type of mutation in histidine operon. In addition to the 
histidine mutation the standard tester strains contain other 
mutations that greatly enhance their ability to detect 
mutagens. One mutation (rfa) causes partial loss of the 
lipopolysaccharide barrier coating the surface of the 
bacteria and increases permeability to large molecules such 
as benzo pyrene that do not penetrate the normal cell wall. 
The other mutation uvrB is a deletion of a gene coding for 
the DNA excision repair system, resulting in greatly 
increased sensitivity in detecting many mutagens. The 
standard tester strains TA98 and TA100 contain R-factor 
plasmid, pKM101. TA98 detect frame shift mutagens 
while TA100 detects base pair  mutagens7 .primarily 
recommended both TA98 and TA100 for routine 
mutagenicity assay. 
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Composition of the Media and Solutions used 
Vogel-Bonner medium E (50X)  
For 1 litre medium  
Ingredient      Per liter 
 Warm distilled H2O (45ºC)    670 ml 
 Magnesium sulfate (MgSO4, 7H2O)    10 g 
 Citric acid monohydrate     100 g 
 Potassium phosphate, dibasic (anhydrous) (K2HPO4)  500 g 
 Sodium ammonium phosphate (NaHNH4PO4, 4H2O)  175 g 
 
The salts were added in the order indicated in the warm water and each salt was allowed to dissolve completely before 
adding the next. Volume was adjusted to 1 liter and then autoclaved before use for 20 min. 
 
0.5 mM hitidine/biotin solution: 
Ingredient  Per 250 liter 
D-Biotin  30.9 mg 
L-Histidine.HCl  24.0 mg 
Distilled H2O  250 ml 
The solution was sterilized by passing through 0.22-µm-membrane filter. 
Top agar 
Ingredient  Per 250 liter 
Agar   6 g 
NaCl   5 g 
Distilled H2O  100 ml 
After dissolving thoroughly the agar was autoclaved for 20 min. 
Salt solution (1.65 M KCl + 0.4 M MgCl2) for S9 mix 
Ingredient    Per 500 liter 
               Potassium chloride (KCl)   61.5 g   
 Magnesium chloride (MgCl2, 6H2O) 40.7 g 
 Distilled H2O    to final volume of 500 ml  
The solution was autoclaved for 20 min. 
0.2 M sodium phosphate buffer, pH 7.4 for S9 mix 
Ingredient     Per 500 ml 
 0.2 M sodium dihydrogen phosphate  60 ml 
 (NaH2PO4, H2O) (13.8.g/500 ml) 
0.2 M disodium hydrogen phosphate  400 ml 
(Na2HPO ) (14.2 g/500 ml) 
The solution was sterilized by autoclaving. 
0.1 M NADP solution (nicotine adenine dinucleotide phosphate) for S9 mix 
Ingredient  Per 5 ml 
 NADP   383 mg 
 Sterile distilled H2O 5 ml 
The tube with this solution was wrapped with metal foil and kept in -20 º freezers. 
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1 M glucose-6-phosphate for S9 mix 
Ingredient     Per 10 ml 
 Glucose-6-phosphate (G-6-P)   2.82 g 
 Sterile distilled H2O    10 ml 
This solution was stored in freezer. 
S9 mix (rat liver microsomal enzymes + cofactors) 
Ingredient      Per 50 ml of S9 mix 
Rat liver S9 (Phenobarbitol induced)  2 ml  
MgCl2-KCl salts     1 ml 
1 M glucose-6-phosphate    0.25 ml 
0.1 M NADP     2 ml 
0.2 M phosphate buffer, pH 7.4   25 ml 
Sterile distilled H2O    16.75 ml 
The solution was prepared fresh and kept in ice. 
Ampicillin solution (8 mg/ml) 
Ingredient     Per 100 ml 
 Ampicillin trihydrate    0.8 g 
 Sodium hydroxide (0.02 N)   100 ml 
The solution was sterilized by passing through 0.22-µm-membrane filter. 
Minimal glucose plate 
Ingredient     Per 1000 ml 
 Agar      15 g 
 Distilled H2O     930ml 
 50 X VB salts     20 ml 
 40 % glucose      50 ml 
15 gm of agar was added to 930 ml of distilled H2O and autoclaved for 20 min. when the solution has cooled slightly, 20 
ml of sterile VB salts and 50 ml of 40% glucose were added. After addition of all the ingredients the solution should be 
stirred thoroughly then was poured 30 ml of it into each petri plate. The 50X VB and 40% glucose were autoclaved 
separately. 
Ampicillin plates and ampicillin/tetracycline plates (for master plates) 
For the tests for ampicillin/tetracycline resistance 
              Ingredient    Per 1000 ml 
               Agar     15 gm 
Distilled H2O    910 ml 
50X VB salts    20 ml 
40% glucose    50 ml 
Sterile histidine HCl, H2O   10 ml 
(2 g per 400 ml H2O)  
Sterile 0.5 mM biotin   6 ml 
Sterile ampicillin solution   3.15 ml 
(8 mg/ml 0.02 N NaOH)       
 __________________________________________ __________________ 
 Sterile tetracycline solution  3.15 ml 
 (8 mg/ml 0.02N NaOH) 
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Agar was autoclaved for water for 20 min. Glucose, 50X 
VB salts and histidine to the hot solution then mixed and 
cooled to approximately 50ºC. Tetracyclin was added only 
for the strain TA102 which is tetracycline resistant. 50X 
VB salts and 40% glucose solutions were sterilized 
separately by autoclaving for 20 min. Histidine and biotin 
solutions was sterilized by filtration. Plates to be used for 
tests of tetracycline and /or ampicillin resistance can be 
stored for approx. 2 months at 4 ºC.  
Preparation of S9 Fraction 
The procedure of Ames et al. and Garner et al. were used 
for the preparation of rat liver homogenate (S9)5 Charles 
river male rats of 150-175 g were fed 0.1% phenobarbital 
in their drinking water for seven days. On day 6, no foods 
were provided for these rats. The next day, they were 
killed for the rat liver homogenate (S9). All steps of this 
preparation were performed at 0C to 4C with cold and 
sterile solutions and glassware. The livers (10-15 gm each) 
were washed in an equal volume of 0.15 M KCl (3 ml/gm 
of wet liver) and homogenized with a homogenizer. The 
homogenate was centrifuged for 10 minutes at 9000g and 
the supernatant that is called as S9 fractions were 
distributed in 2 ml aliquots in small sterile plastic tubes, 
quickly frozen and stored at -80C. The S9 mix was 
prepared following the method of Maron and Ames. 
Bacterial Mutagenicity assay: 
Standard mutagenicity assay tests were performed on 
TA98 and TA 100 strains5. The test drug CHQ was 
dissolved in distilled water and its different concentrations 
(10, 100, 500, 1000 µg/plate) were used in mutagenicity 
assay. In the assay, 0.1 ml/plate of the different 
concentrations of CHQ (i.e. 0.1 ml containing 10, 100, 500 
and 1000 µg/plate) were used. The plates were inverted 
within 1h and placed in a dark vented incubator at 37°C for 
48 h. Similar experiments were carried out for positive 
mutagens (4-nitro-o-phenylenediamine for TA98 and SA 
for TA100) and negative control in absence of S9 mix. 
Four plates were used for each concentration tested and for 
both positive and negative controls. After 48 h of 
incubation, the revertant colonies on the test plates were 
counted. The presence of the background lawn on all the 
plates was confirmed. A similar experiment was also 
carried out using liver homogenate (S9) fractions. Positive 
mutagens 2-AF was used for TA98 experiments with S9 
mix. Due to shortage of time similar experiment with 
TA100 was not been able to carry out. The spontaneous 
reversion rates of these two different Salmonella strains 
were checked and were similar as reported earlier. 
Statistical Analysis 
The results of all the mutagenicity assays were analysed 
using Dunnett’s multiple comparison4 with solvent treated 
control. The level of significance is given in the respective 
tables. 
RESULT: 
Table 1 and Table 2 are summaries of the results of the 
Ames mutagenicity assay in salmonella typhimurium 
strains TA100 and TA98 after CHQ treatment. A 
significant increase in revertant colonies was observed at 
the doses 100μg/plate to 1000 μg/plate in the salmonella 
strain TA100 when compared to solvent treated control. At 
5000μg/plate a significant decrease in the revertant 
colonies indicate that the CHQ was toxic at this dose. The 
results of solvent treated control and positive control are at 
per the values reported by other authors.No significant 
revertant colonies were observed in any of the 
concentration tested in case of salmonella strain TA98 
either with or without S9 activation. So this result shows 
that the CHQ was not mutagenic in salmonella strain 
TA98. This overall results indicate that the CHQ is a 
weakly mutagenic in salmonella strain TA100 which 
detect the base pair substitution mutants. The number of 
revertant colonies of strain TA100 and TA98 were 
significantly decreased at 5000μg/plate dose when 
compared to solvent treated control. This observation 
suggests that at this dose the drug CHQ shows toxic effects 
in both the strains. 
 
Table 1: Number of revertants induced by chloroquine in salmonella plate incorporation test using TA 100 
Chemicals                              Revertants/plate  
(μg/plate)                                                                           -S9                                          
Solvent control (100μl distilled water)                                        155.00 ± 12.355 
Chloroquine 
10                                                                                    200.25 ± 28.35 
100                                          285.75 ±   7.27* 
500                                           274.50 ± 29.01* 
1000                                           293.25 ± 28.70* 
5000                                                                                                             109.75 ±  8.99 
Positive control 
SA (1.5μg/plate)                                           1139.5 ± 70.33                                                              
    
-S9 = without metabolic activation. All data represented here are Mean ± SD of four plates. Results for each concentration were compared with the 
solvent treated control by Dunnet’s multiple comparison test.          SA=Sodium azide.        * p< 0.01 
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Table 2: Number of revertants induced by chloroquine in salmonella plate incorporation test using TA 98 strain 
Chemicals           Revertants/plate  
(μg/plate)                                          -S9                                   +S9 
Solvent control  
(100μl distilled water)                                            44.75 ± 3.77                    46.25 ± 5.74 
Chloroquine 
10                                                                           43.25 ± 6.70                  44.0 ± 4.69                        
100                                                                         51.75 ± 8.50                     54.0 ± 5.29 
500                                                                         58.00 ± 8.86                     56.75 ± 6.39 
1000                                                                       64.00 ± 8.28                     62.50 ± 3.39 
5000                                                                       23.50 ± 6.25                     19.50 ± 9.88 
Positive control                                        
NPD (20μg/plate)                                                 1272.25 ± 168.64                                                           
2-AF (10μg/plate)                                                                                         2317 ± 236.63 
- S9 = without metabolic activation.                   + S9 = with metabolic activation. 
All data represented here are Mean ± SD of four plates. Results for each concentration were compared with the solvent treated control by D unnet’s 
Multiple comparison test.  NPD=4-nitro-o-phenylenediamine, 2AF=2-aminofluorene. 
CONCLUSION: 
The results of the mutagenicity assay indicate that 
chloroquine is a weak mutagen in Salmonella strain 
TA100. CHQ showed a very weak mutagenic effect in the 
absence of S9 mix in strain TA100. But this compound 
didn’t show any mutagenic effect on TA98 strain both in 
presence or absence of S9 mix. This observation suggests 
that metabolic products of CHQ might not play a 
significant role in induction of mutation. CHQ is rapidly 
and almost completely absorbed from the GI tract and 
localized in tissues especially in kidney, liver, lung, spleen 
and in skin. From the tissue this drug is slowly excreted 
and the drug-metabolites may be present in the tissue for 
months or even years . Moreover the recommended dose 
for CHQ is relatively high (about 300 mg per tablet) . So, 
exposure of CHQ in human tissue for prolonged time 
period could increase the risk of mutation in tissue cells 
though the compound is found to be weakly mutagenic by 
Ames test. Our results also indicate chloroquine might be 
able to induce base pair mutation than that of frame shift 
mutation. Taking together these findings indicate that it is 
weak mutagenic compound and the use of this drug should 
monitor properly and excessive use of this drug should be 
avoided.  
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